Study demonstrates the safety and feasibility of psilocybin for the treatment of mental health disorders.
Psilocybin can restore mGluR2 levels in the prefrontal cortex, and this leads to a reduced risk of relapse for those with alcohol use disorder.
A growing body of evidence suggests psychedelics including psilocybin and LSD show promise in providing lasting relief from symptoms for those suffering some mental health disorders. Researchers found DOI, a similar drug to LSD, reduced negative behavioral responses following fear triggers in mouse models of anxiety.
Psilocybin, a natural psychoactive compound currently being considered for the treatment of depression, alters people's emotional states while listening to music. While listening to music, those who used psilocybin reported enhanced emotional processing. Researchers say combining music with psychedelic therapy may have positive benefits for those suffering from depression.
From treating depression and other mental health disorders, to helping relieve chronic pain, researchers discuss the advantages and implications of psychedelic treatments.
One dose of psilocybin, the psychoactive compound found in magic mushrooms, increases dendritic spine density within 24 hours. The neurobiological changes lasted for a month following psilocybin exposure. Additionally, mice subjected to stress showed behavioral improvements and increased neurotransmitter activity after psilocybin exposure.
Psilocybin, the psychoactive compound found in magic mushrooms, is as effective at treating depression as conventional SSRI antidepressants. Researchers report, that although not significantly significant, early findings reveal those treated with psilocybin experienced more rapid and greater reductions in depression symptoms than those treated with SSRIs.
A mouse study refutes the common belief that psilocybin's ability to produce an anti-depressant effect is attributed to the psychedelic experience it creates. Blocking the psychedelic effect did not affect psilocybin's anti-depressant effects.
From microdosing to improve cognition, to treating a range of mental health disorders, researchers evaluate the rise in the use of psychedelics and their potential as medicines.
A new small scale study reveals psilocybin appears to have a beneficial effect for chronic migraine sufferers.
Two doses of psilocybin in combination with therapy rapidly and significantly reduces symptoms in those with major depressive disorder. The effects appear to last for up to four weeks.
Researchers have uncovered the structure of psychedelic compounds when they actively bind to the 5-HT2A serotonin receptor on the surface of brain cells. The discovery could lead to the exploration of more precise compounds that offer the therapeutic effects of psychedelics for mental health disorders, but without the hallucinations.
